iSTAR Medical’s “emerging technology” presented at IGC

MINIjectTM, iSTAR Medical’s minimally invasive glaucoma surgery (MIGS) device, has been presented as part of the ‘Emerging Technologies’ session at the prestigious 2020 virtual Interventional Glaucoma Congress (IGC) meeting. Dr Paul Singh, who presented iSTAR Medical’s technology, is a glaucoma specialist, President of The Eye Centers of Racine & Kenosha (Wisconsin, USA) and one of the implanting surgeons in MINIject trials.

“MINIject is able to maintain significant intraocular pressure reduction in the longer-term, with a reassuring safety profile, thanks to its innovative bio-integration and anti-inflammatory properties,” he explained. “The results seen so far in over 130 patients are certainly promising, particularly considering these results are achieved in a standalone procedure,” he added.

The IGC meeting is an invitation-only, think tank–style meeting for glaucoma specialists to exchange ideas on innovations and advanced practices for improved patient care. It is chaired by glaucoma specialists Doctors Ike Ahmed, Rick Lewis, and Arsham Sheybani.


iSTAR Medical wins BVA Award 2020!

iSTAR Medical has been awarded the 2020 BVA Venture Company of the Year at the BVA Award virtual ceremony today. The BVA Award is organised by the Belgian Venture Capital & Private Equity Association to reward and celebrate high-performing Belgian companies backed by private equity or venture capital funds.

“We are honoured and excited by the BVA award recognition. We have come a long way since MINIject was implanted in the first patient in 2017, thanks to our investors who believed in the technology and made it possible. MINIject has now been implanted in over 130 patients and its remarkable results are a game changer for patients with glaucoma,” stated Michel Vanbrabant, iSTAR Medical CEO.

iSTAR Medical is a medtech company pioneering minimally-invasive ophthalmic implants for powerful, safe and enduring treatment of patients with glaucoma. The company is headquartered in Wavre, Belgium.

iSTAR Medical’s CEO at OIS Glaucoma Innovation Showcase

OIS Glaucoma Showcase

CEO Michel Vanbrabant will illustrate the latest results for iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) device MINIject at the Glaucoma Innovation Showcase today. iSTAR Medical was selected as one of eight companies to showcase innovative glaucoma treatments to prospect investors at today’s meeting organised by the Ophthalmology Innovation Summit (OIS).

iSTAR Medical recently announced consistently positive safety and efficacy outcomes in over 130 patients implanted with MINIject, and presented subsets of these data at the European Society of Cataract and Refractive Surgery (ESCRS) meeting.

“MIGS are the most promising and fastest-growing therapy for glaucoma,” explained Vanbrabant, “we are truly excited about the latest, promising data in a larger patient population that tout MINIject as potentially best-in-class.”

OIS facilitates meaningful exchange of information to accelerate the development of novel therapies that address unmet clinical needs. It was founded by ophthalmologist/venture capitalist Emmett Cunningham of Blackstone Life Sciences and venture capitalist Bill Link of Versant Ventures/Flying L Partners.

Registration is free for the OIS glaucoma innovation showcase meeting: click here.

Meet iSTAR Medical’s new logo

Logo iSTAR Medical

Let us introduce you to iSTAR Medical’s new logo.

Our ‘eye’ embeds our purpose: improving the vision and lives of patients with glaucoma through powerful and safe ophthalmic implants with bio-integration.

The foundation of our technology is the proprietary, microporous, anti-fibrotic STAR® material, combined with intuitive access into the supraciliary space.

The unique outcomes: powerful enhancement of natural flow, bio-integration with surrounding tissue, and anti-inflammatory properties resulting in enduring results.

MINIject’s STAR-I and II trial data to be presented at ESCRS

Positive results from two clinical trials of iSTAR Medical’s micro-invasive glaucoma surgery (MIGS) implant MINIjectTM  will be presented at the European Society of Cataract and Refractive Surgery (ESCRS) meeting on October 2-4.

Read more

MINIject’s data presented at Ophthalmology Futures Forum

CEO Michel Vanbrabant will present positive outcomes for iSTAR Medical’s MIGS device MINIjectTM in over 130 glaucoma patients at the Ophthalmology Futures Forum today.

Read more

Journal of Glaucoma published MINIject six-month clinical data

Successful primary endpoint results of MINIject in the European clinical trial STAR-II have been published in the peer-reviewed Journal of Glaucoma. The data confirm that MINIject met the study primary endpoints with over 75 percent of patients reaching prospectively defined success.

Read more

iSTAR Medical nominated for BVA Award

iSTAR Medical has been selected as one of three nominees for the 2020 BVA Award “Venture company of the year”. The Award is organised by the Belgian Venture Capital & Private Equity Association to reward and celebrate high-performing Belgian companies backed by private equity or venture capital funds.

Read more